GSK Paxil Pediatric Safety Concerns Have No Effect On Adult Use, FDA Says
Executive Summary
FDA is reassuring adult users about the safety of GlaxoSmithKline's Paxil in light of reports of an increased risk of suicidal thoughts in pediatric patients taking paroxetine
You may also be interested in...
GSK Faces New York Suit Over Paxil: Publish Or Punish?
GlaxoSmithKline's failure to publish pediatric safety study results for its antidepressant Paxil (paroxetine) is one basis of fraud allegations lodged against the company by New York Attorney General Eliot Spitzer
GSK Faces New York Suit Over Paxil: Publish Or Punish?
GlaxoSmithKline's failure to publish pediatric safety study results for its antidepressant Paxil (paroxetine) is one basis of fraud allegations lodged against the company by New York Attorney General Eliot Spitzer
Antidepressant Suicide Data To Be Evaluated For FDA By Columbia University
Columbia University will coordinate a review of pediatric antidepressant suicidal event data for FDA